S-1: Virpax Pharmaceuticals Seeks to Raise Capital Through Public Offering of Common Stock and Pre-Funded Warrants

Virpax Pharmaceuticals is launching a best efforts public offering of common stock and pre-funded warrants to fund its Probudur IND filing and for general corporate purposes.

Summary

• Virpax Pharmaceuticals, a preclinical-stage pharmaceutical company, has filed a registration statement for a proposed public offering.
• The offering includes shares of common stock and pre-funded warrants, with the number of shares decreasing on a one-for-one basis for each pre-funded warrant sold.
• The company's common stock is listed on the Nasdaq Capital Market under the symbol VRPX, with the last reported sale price on July 26, 2024, being $1.38 per share.
• The offering price will be negotiated between the company and investors, potentially at a discount to the current market price.
• RBW Capital Partners LLC, acting through Dominari Securities LLC, is the exclusive placement agent for the offering.
• The offering is on a 'best efforts' basis, meaning there's no guarantee that all or any of the securities will be sold.
• The offering is expected to terminate on August [], 2024, unless fully subscribed or terminated earlier.
• Net proceeds will be used to fund the planned Investigational New Drug (IND) filing for Probudur, working capital, and general corporate purposes.
• The company is an emerging growth company and a smaller reporting company, allowing for reduced public company reporting requirements.
• Virpax has recently faced challenges including Nasdaq compliance issues related to stockholders' equity and minimum bid price, as well as litigation with Sorrento Therapeutics and Scilex Pharmaceuticals.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While there are positive developments such as positive study results for Probudur and warrant exercises, the company faces significant financial challenges, Nasdaq compliance issues, and litigation risks, leading to an overall cautious outlook.

Positives

• The company intends to use the net proceeds from this offering to fund its ongoing activities in connection with its planned IND filing for Probudur.
• The company has regained compliance with the Nasdaq minimum bid price rule.
• Positive results were announced for a Swine Model pilot study for Probudur, demonstrating a long-term, slow-release profile and good tolerability.
• The company has repaid a secured note in full using proceeds from warrant exercises.

Negatives

• The offering is on a 'best efforts' basis, meaning there's no guarantee that all or any of the securities will be sold.
• The company has a history of operating losses and will need to obtain substantial additional funding.
• The company's current cash position is not sufficient to fund operations through the third quarter of 2024.
• The company may be delisted from the Nasdaq Capital Market if it fails to meet continued listing requirements.
• The company recently settled litigation with Sorrento and Scilex for $6 million plus royalties.
• The company has a stockholders deficit of $1,213,384 as of March 31, 2024.
• The company will need additional future financing which may not be available on acceptable terms, if at all and will result in the issuance of additional securities being issued which will cause investors to experience further dilution.

Risks

• The company requires substantial additional capital to fund its operations, and failure to obtain necessary financing could hinder development and commercialization of its drugs.
• Recent litigation has negatively impacted the company's cash position.
• The company's management has broad discretion in using the net proceeds from the offering.
• Failure to meet the continued listing requirements of the Nasdaq Capital Market could result in a delisting of the company's common stock.
• Investors will experience immediate and substantial dilution in the net tangible book value of their shares.
• There is no public market for the pre-funded warrants being offered.
• The company's product candidates are still in preclinical or early stages of clinical development.
• The company is dependent on third parties to manufacture its product candidates and conduct its clinical trials.
• The company's ability to maintain or protect the validity of its intellectual property is uncertain.

Future Outlook

The company expects to require substantial additional capital until its operations generate sufficient revenue to cover its expenses.

Industry Context

The document does not provide specific details on how this announcement relates to broader industry trends or competitors, but it is implied that the company is operating in the competitive pharmaceutical industry.

Management Changes

Legal Proceedings

• The company recently settled litigation with Sorrento Therapeutics and Scilex Pharmaceuticals for $6 million plus royalties.

Stakeholder Impact

• Shareholders will experience potential dilution due to the public offering.
• Employees' job security could be affected by the company's financial situation.
• The company's ability to develop and commercialize its product candidates will impact patients.
• Suppliers and creditors face risks related to the company's ability to meet its obligations.

Next Steps

• The company plans to file an Investigational New Drug (IND) application for Probudur.
• The company will continue to work towards regaining compliance with Nasdaq listing requirements.
• The company and the Investor will negotiate in good faith in order to agree upon and consummate an equity or debt financing (a Subsequent Financing) of not less than $5.0 million as soon as practicable after the closing date of the Financing.

Key Dates

Keywords

public offering, pre-funded warrants, common stock, Probudur, pharmaceuticals, Nasdaq, VRPX, IND filing, capital raise, Virpax